ASP 0777

Drug Profile

ASP 0777

Alternative Names: ASP0777

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma US
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Aug 2013 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
  • 17 Nov 2011 Astellas Pharma completes a phase I trial in Alzheimer's disease in USA (NCT01406145)
  • 22 Sep 2011 Astellas Pharma completes enrolment in its phase Ib trial for Alzheimer's Disease in USA (NCT01406145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top